Jun 03–06, 2024 | Santa Fe Community Convention Center, Santa Fe, NM, United States
Scientific Organizers:
Leonard Petrucelli, Stacie Weninger, and Soyon Hong

-
Scientific Organizers: Leonard Petrucelli, Stacie Weninger, and Soyon Hong
Leonard Petrucelli
Stacie Weninger
Soyon Hong
***Meeting program subject to change.
Available Formats: = In PersonMerchandise Options
Registration Options
Booking Function
Fundraising
Monday, June 3, 2024
Tuesday, June 4, 2024
Aging, the Immune System and Neurodegeneration
Connecting Human Microglia States to Function in Health and Disease
Transcriptional Regulation of Macrophage Development
Therapeutic Development for Neurodegenerative Disorders
Epigenetic Regulation of Microglia
Spatial Transcriptomics Reveals Neuroimmune Mechanisms of Aβ Clearance in Immunized Alzheimer’s Disease Patients
Single Cell Analysis Reveals a Neurodegeneration Specific Microglia Population Resistant to CSF1R Inhibition in a Mouse Model with FTLD-like Pathology
Beyond the Shuttle: Advances in Brain Delivery of Biologics for the Treatment of Neurodegenerative Diseases
Genome-Wide CRISPR-Cas9 Based Screening for Modifiers of Lysosomal GCase Activity Uncovers Candidate Risk Factors for Parkinson Disease
An Integrated Multimodal Cell Atlas of Alzheimer's Disease
Controlling Endogenous mRNA Localization in the Peripheral and Central Nervous Systems in vivo
Human Microglia Expressing High Levels of CD74 Expression are Associated with Activation and Cognitive Decline
Dire Straits: Loss of Translational Regulation of SNCA by Iron Unifies the Genetics of PD and LBD at the SNCA Locus
Leveraging Human Genetics for Novel Therapeutic Approaches for Alzheimer's Disease
PGRN/ApoE
Role of APOE in Modulating the Innate and Adaptive Immune Response in Neurodegeneration
Short Talk: Short Talk: Alzheimer’s Disease Microglia Exhibit Enriched Proliferation-related Clonal Somatic Mutations Associated with Inflammatory States
Short Talk: Short Talk: Anti-amyloid Immunotherapy Induces Sustained Microglial and Immune Alterations
Wednesday, June 5, 2024
Neuroimmune Signaling Across Gut-Brain Axis Modulates Brain Synucleinopathy
Integrated Proteomics for Therapeutic Target and Biomarker Discovery in Alzheimer’s Disease
Tmem/PGRN
Short Talk: Short Talk: LMO7 Modulates Tau Levels by Regulating CHIP-BAG5 Interplay: Novel Insights into Tauopathy Mechanisms
Short Talk: Short Talk: Vascular–immune Epigenetic Mechanisms Underlying Age-related Brain Disorders
Short Talk: Short Talk: The Alzheimer’s Risk Genes MS4A4A and MS4A6A Cooperate to Regulate Key Microglial Functions
Short Talk: Short Talk: Polyserine Domain RNA-binding Proteins as Cellular Factors Enhancing Tau Aggregation
Group Leader & Professor
Associate Professor, Director and Neurogeneticist
Senior Investigator
Drug Maker in Residence
Executive Editor
In vivo Proteomic Tools TurboID
Cognitively Healthy Centenarians are Genetically Protected Against Alzheimer’s Disease
Targeting Known and Novel Receptors to Deliver Drugs for Neurodegenerative Diseases
Short Talk: Short Talk: Transcriptomic Changes in Lewy Body Disease and Alzheimer's Disease Linked to Selective Regional and Neuronal Vulnerability
Short Talk: Short Talk: Unveiling Microglial Heterogeneity in Spatial Context
Thursday, June 6, 2024
Modeling Early Alzheimer’s Disease in Human Context
Chimeroids as Avatars to Investigate Brain Diseases
Elucidating Mechanisms and Therapeutic Targets for Neurodegenerative Diseases by CRISPR-Based Functional Genomics
Short Talk: Short Talk: Metabolic Perturbation in Ependymal Cells Leads to Progressive Peri-ventricular Pathology and Recapitulates Alzheimer’s Disease Pathogenesis
Short Talk: Short Talk: Therapeutic Potential of Human Microglial Transplantation in a Chimeric Model of CSF1R-related Leukoencephalopathy
Short Talk: Short Talk: The Innovative Neuron-Glial Brain Assembloid Model of Alzheimer’s Disease Reveals the Differential Role of ApoE Isoforms in Pathological Tau Propagation
Short Talk: Short Talk: Unravelling LTP-like Synaptic Plasticity in Human Cortical Biopsies on Microelectrode Arrays
TMEM106B Risk SNP Alters Disease Duration and Fibril Deposition in FTLD-TDP
PTPσ-Mediated PI3P Regulation as a Therapeutic Strategy for C9ORF72-ALS/FTD
Developing Parkin Activators to Enhance Mitochondrial Function for the Treatment of Parkinson’s Disease
Enabling a Precision Medicine Approach to Target and Biomarker Discovery in Alzheimer’s Disease: Accelerating Medicines Partnership® Alzheimer’s Disease (AMP AD)
Targeting SARM1 Inhibition Provides a Promising Therapeutic Strategy for DNA Damage-Induced Neurodegenerative Diseases, Including Amyotrophic Lateral Sclerosis (ALS)
TYK2 Kinase as a Novel Therapeutic Target in Alzheimer’s Disease
GPR34 Loss-of-function Rescues TREM2 Metabolic Dysfunction and Promotes Responsive Microglial States
Decreased Lipidated ApoE-receptor Interactions Confer Protection against Pathogenicity of ApoE and its Lipid Cargoes
Precision Medicine in Neurodegeneration
Prime Editing as a Curative Therapeutic Approach for Neurodegenerative Diseases
Addressing CNS Indications using a Novel Di-siRNA Modality for Improved Potency, Distribution, and Duration
ALS and Neurodegeneration Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia
Friday, June 7, 2024
Subscribe for Updates